Cutaneous T-cell lymphomas and their management strategies

被引:1
作者
Pandey, S. S. [1 ]
Garg, S. [2 ]
Dwivedi, A. N. D. [3 ]
Tripathi, R. [4 ]
Tripathi, K. [2 ]
Bansal, M. [1 ]
机构
[1] Banaras Hindu Univ, Inst Med Sci, Dept Dermatol & Venereol, Varanasi 221005, Uttar Pradesh, India
[2] Banaras Hindu Univ, Inst Med Sci, Dept Gen Med, Varanasi 221005, Uttar Pradesh, India
[3] Banaras Hindu Univ, Inst Med Sci, Dept Radiodiag & Imaging, Varanasi 221005, Uttar Pradesh, India
[4] Banaras Hindu Univ, Inst Med Sci, Dept Oral & Maxillofacial Surg, Varanasi 221005, Uttar Pradesh, India
关键词
Cutaneous T-cell lymphomas; management; mycosis fungoides; review; systemic retinoids; EPSTEIN-BARR-VIRUS; WORINGER-KOLOPP-DISEASE; PHASE-II TRIAL; TERM-FOLLOW-UP; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; PROGNOSTIC-FACTORS; CLINICAL CHARACTERISTICS; EUROPEAN-ORGANIZATION; INTERNATIONAL-SOCIETY;
D O I
10.4103/0019-509X.146782
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of lymphoproliferative disorders characterized by the proliferation of skin-homing post-thymic T-cells. It is the second most common extranodal non-Hodgekin's lymphoma. Many variants of mycosis fungoides and CTCLs are known to date, differing in clinical, histological, and immunophenotypic characteristics. Oral involvement has also been reported rarely in CTCLs. Treatment depends on the disease stage or the type of variant. New insights into the disease and the number of emerging novel therapeutic options have made it an interesting area for dermatologists and medical oncologists.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 150 条
[71]   Selectins and their ligands: Current concepts and controversies [J].
Kansas, GS .
BLOOD, 1996, 88 (09) :3259-3287
[72]   PHASE-II STUDY OF RECOMBINANT HUMAN INTERFERON-GAMMA FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA [J].
KAPLAN, EH ;
ROSEN, ST ;
NORRIS, DB ;
ROENIGK, HH ;
SAKS, SR ;
BUNN, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (03) :208-212
[73]   Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue [J].
Karenko, L ;
Hahtola, S ;
Päivinen, S ;
Karhu, R ;
Syrjä, S ;
Kähkönen, M ;
Nedoszytko, B ;
Kytölä, S ;
Zhou, Y ;
Blazevic, V ;
Pesonen, M ;
Nevala, H ;
Kupponen, N ;
Sihto, H ;
Krebs, I ;
Poustka, A ;
Roszkiewicz, J ;
Saksela, K ;
Peterson, P ;
Visakorpi, T ;
Ranki, A .
CANCER RESEARCH, 2005, 65 (18) :8101-8110
[74]   Involvement of the tongue by lymphomatoid papulosis [J].
Kato, N ;
Tomita, Y ;
Yoshida, K ;
Hisai, H .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1998, 20 (05) :522-526
[75]  
KAUDEWITZ P, 1990, CURR PROBL DERMATOL, V19, P150
[76]   Fascin expression in CD30-positive cutaneous lymphoproliferative disorders [J].
Kempf, W ;
Levi, E ;
Kamarashev, J ;
Kutzner, H ;
Pfeifer, W ;
Petrogiannis-Haliotis, T ;
Burg, G ;
Kadin, ME .
JOURNAL OF CUTANEOUS PATHOLOGY, 2002, 29 (05) :295-300
[77]  
Kim YH, 2004, J INVEST DERMATOL, V122, pA57
[78]   Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression [J].
Kim, YH ;
Liu, HL ;
Mraz-Gernhard, S ;
Varghese, A ;
Hoppe, RT .
ARCHIVES OF DERMATOLOGY, 2003, 139 (07) :857-866
[79]   Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma [J].
Kim, Youn H. ;
Girardi, Michael ;
Duvic, Madeleine ;
Kuzel, Timothy ;
Link, Brian K. ;
Brown, Lauren Pinter ;
Rook, Alain H. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (06) :975-983
[80]  
Kodama K, 1996, Rinsho Ketsueki, V37, P65